These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31981542)

  • 1. Taking the neglected out of neglected tropical diseases.
    The Lancet Global Health
    Lancet Glob Health; 2020 Feb; 8(2):e152. PubMed ID: 31981542
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence for visceral leishmaniasis elimination in Nepal.
    Banjara MR; Joshi AB
    Lancet Glob Health; 2020 Feb; 8(2):e161-e162. PubMed ID: 31981545
    [No Abstract]   [Full Text] [Related]  

  • 3. Leishmaniasis: current challenges and prospects for elimination with special focus on the South Asian region.
    Karunaweera ND; Ferreira MU
    Parasitology; 2018 Apr; 145(4):425-429. PubMed ID: 29642962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visceral Leishmaniasis.
    Famularo G; Mancini S
    Mayo Clin Proc; 2016 Sep; 91(9):1322-3. PubMed ID: 27594193
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress in the Mathematical Modelling of Visceral Leishmaniasis.
    Rock KS; Quinnell RJ; Medley GF; Courtenay O
    Adv Parasitol; 2016; 94():49-131. PubMed ID: 27756459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic leishmaniasis--first case report from Nepal.
    Sharma SK; Das ML; Rijal S; Sah SP; Koirala S
    Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):749-50. PubMed ID: 12041549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptation of Leishmania donovani to cutaneous and visceral environments: in vivo selection and proteomic analysis.
    McCall LI; Zhang WW; Dejgaard K; Atayde VD; Mazur A; Ranasinghe S; Liu J; Olivier M; Nilsson T; Matlashewski G
    J Proteome Res; 2015 Feb; 14(2):1033-59. PubMed ID: 25536015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines for visceral leishmaniasis: A review.
    Jain K; Jain NK
    J Immunol Methods; 2015 Jul; 422():1-12. PubMed ID: 25858230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis.
    McCall LI; Zhang WW; Ranasinghe S; Matlashewski G
    Vaccine; 2013 Feb; 31(10):1420-5. PubMed ID: 23219435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological markers for leishmania donovani infection in Nepal: Agreement between direct agglutination test and rK39 ELISA.
    Khanal B; Rijal S; Ostyn B; Picado A; Gidwani K; Menten J; Jacquet D; Lejon V; Chappuis F; Boelaert M
    Trop Med Int Health; 2010 Nov; 15(11):1390-4. PubMed ID: 21998875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of Leishmania donovani infection in high-transmission foci in Nepal.
    Rijal S; Uranw S; Chappuis F; Picado A; Khanal B; Paudel IS; Andersen EW; Meheus F; Ostyn B; Das ML; Davies C; Boelaert M
    Trop Med Int Health; 2010 Jul; 15 Suppl 2():21-8. PubMed ID: 20487421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laryngeal leishmaniasis: case report of a rare infection.
    Teemul TA; Giles-Lima M; Williams J; Lester SE
    Head Neck; 2013 Sep; 35(9):E277-9. PubMed ID: 22972594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of visceral leishmaniasis elimination program in India: a picture imperfect.
    Gurunath U; Joshi R; Agrawal A; Shah V
    Expert Rev Anti Infect Ther; 2014 Aug; 12(8):929-35. PubMed ID: 24930676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphadenopathy in a child with Indian kala-azar in Dharan, Nepal.
    Singh K; Singh R; Parija SC
    Indian Pediatr; 1998 Nov; 35(11):1125-6. PubMed ID: 10216552
    [No Abstract]   [Full Text] [Related]  

  • 15. The hidden burden of Neglected Tropical Diseases: a call for inter-sectoral collaboration in Nepal.
    Dhimal M; Karki KB
    J Nepal Health Res Counc; 2014; 12(28):I-IV. PubMed ID: 26032064
    [No Abstract]   [Full Text] [Related]  

  • 16. Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action.
    Alvar J; den Boer M; Dagne DA
    Lancet Glob Health; 2021 Dec; 9(12):e1763-e1769. PubMed ID: 34798033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.
    Zhu X; Van Horn KS; Barber MM; Yang S; Wang MZ; Manetsch R; Werbovetz KA
    Bioorg Med Chem; 2015 Aug; 23(16):5182-9. PubMed ID: 25749014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of microscopy and polymerase chain reaction for the diagnosis of suspected visceral leishmaniasis patients in Nepal.
    Pandey K; Mallik AK; Pyakurel S; Pun SB; Pandey BD
    Kathmandu Univ Med J (KUMJ); 2013; 11(41):14-7. PubMed ID: 23774406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing a CASPER Survey to Assess the Prevalence of Risk Factors for Neglected Tropical Diseases in Texas.
    Smitherman S; Hammond T; Goldberg D; Horney J
    Health Secur; 2017; 15(3):238-243. PubMed ID: 28636445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LD body-negative bone marrow cases of kala-azar in Dharan, Nepal.
    Karki P; Parija SC; Koirala S
    J Commun Dis; 1999 Dec; 31(4):261-2. PubMed ID: 10937305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.